Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic appointed Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026, succeeding co-founder Andreas Muehler who will remain as a consultant. Dr. Panzara brings over 25 years of experience in neurology, having overseen global regulatory approvals for key MS therapies like LEMTRADA and AUBAGIO during his tenure at Sanofi Genzyme.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.